Clinical Trials Logo

Central Nervous System Diseases clinical trials

View clinical trials related to Central Nervous System Diseases.

Filter by:

NCT ID: NCT04692311 Completed - Clinical trials for Central Nervous System Diseases

Pilot Study Concerning an Intelligent Activity-based Client-centred Training System in Neurorehabilitation

i-ACT
Start date: January 4, 2016
Phase: N/A
Study type: Interventional

The pilot study was performed to evaluate the usability, credibility and expectancy of an intelligent, activity-based client-centred training system (i-ACT), and the motivation towards its use in neurological rehabilitation over a short period of time.

NCT ID: NCT04640077 Completed - Alzheimer Disease Clinical Trials

A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

Start date: November 23, 2020
Phase: Phase 2
Study type: Interventional

The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer's disease and to validate video scale assessments.

NCT ID: NCT04571996 Completed - CNS Disease Clinical Trials

Blood-Brain Barrier Penetration of Therapeutic Agents in Human

BRIAN
Start date: October 29, 2020
Phase: Phase 1
Study type: Interventional

This is a phase 1, open-label, non-randomized, exploratory, repeated dose PK study performed at a single centre. Up to 6 evaluable subjects are planned. The subjects will receive p.o. doses of ODM-104 for 5-7 days. Single dose of paracetamol will be administered p.o. together with ODM-104 for purposes of comparison.

NCT ID: NCT04494828 Completed - Clinical trials for Central Nervous System Diseases

Impact Dexmedetomidine on Postoperative Delirium in Patients After Intracranial Operation for Brain Tumor

Start date: August 10, 2020
Phase: Phase 4
Study type: Interventional

Postoperative delirium is one of the most common serious complications after major surgery and is associated with undesirable consequences. Prevention of postoperative delirium is recommended in the clinical guidelines and consensus statements. Dexmedetomidine, a highly selective α2-adrenergic receptor agonist, has been investigated as a pharmacological intervention to prevent postoperative delirium. Several randomized controlled trials have shown that prophylactic use of low-dose dexmedetomidine may decrease the incidence of postoperative delirium in patients after cardiac and non-cardiac operations. However, neurosurgical patients are often excluded from previous studies due to potential consciousness and cognition impairment. The investigators design this pilot study aiming to clarify the feasibility and safety of use of low-dose dexmedetomidine for prevention of postoperative delirium in patients after intracranial operation for brain tumor.

NCT ID: NCT04467762 Completed - Critical Illness Clinical Trials

Neurocognitive Impairment in Pediatric Patients With Meningoencephalitis and Sepsis-associated Encephalopathy

NCIPED
Start date: August 3, 2020
Phase:
Study type: Observational

Neurocognitive impairment is frequently observed in pediatric patients with meningoencephalitis (ME) and sepsis-associated encephalopathy (SAE) which represent two relevant central nervous system (CNS) diseases in pediatric patients. It is uncertain, if the the origin of the disease, located primarily in the CNS of patients with ME or secondarily in patients with SAE in the course of sepsis, is of importance for the severity of injury to the brain. Prospective clinical studies combining clinical and laboratory examinations including specific biomarkers of neuroaxonal injury were not performed in a comparative study. Biomarkers of neuroaxonal injury are therefore not only of great interest to detect and monitor neurocognitive impairment but also to quantify the severity of brain injury in patients with ME and SAE.

NCT ID: NCT04445831 Completed - Dementia Clinical Trials

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease

Start date: July 31, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a multicenter, double blind, randomized, placebo-controlled study to evaluate the safety, tolerability and immunogenicity of different doses, regimens and combinations of Tau targeted vaccines in participants with early Alzheimer's Disease.

NCT ID: NCT04441190 Completed - Stroke Clinical Trials

Multi-mode Stroke Rehabilitation System: Development and Validation of Clinical Efficacy

Start date: August 3, 2020
Phase: N/A
Study type: Interventional

The specific study aims will be: 1. To develop the novel, digital, and interactive MSR system of arm and hand with integrated digital action observation therapy (AOT) and mirror therapy (MT). 2. To pilot usability testing for examining the feasibility of this new MSR system from the users' experiences and feedback. 3. To examine the treatment effects of digital AOT, digital MT and a control intervention in patients with stroke by conducting a randomized controlled trial. 4. To identify who will be the possible good responders to digital AOT and MT based on their baseline motor function and mental imagery abilities.

NCT ID: NCT04313686 Completed - Epilepsy Clinical Trials

Mindfulness-based Intervention to Promote Psychological Wellbeing in People With Epilepsy

Start date: January 10, 2018
Phase: N/A
Study type: Interventional

The efficacy of mindfulness-based intervention (MBI) for epilepsy has yet to be thoroughly investigated. Hence, the aim of the present study is to examine the effects of MBI on the psychological wellbeing of people with epilepsy (PWE) using a randomized trial design. Key outcomes include depression, anxiety and quality of life. Our primary objective was to evaluate the effect of mindfulness-based therapy on anxiety, depression, epilepsy specific QOL, and life satisfaction in PWE, applying the concept of Reliable Change Index. The secondary objective was to assess whether the results correlate with the level of mindfulness. Study results may be used to decide whether it is worth offering mindfulness training for PWE as an alternative therapy to cope and improve seizure management.

NCT ID: NCT04283253 Completed - Stroke Clinical Trials

Predictors of Response in Chronic Stroke

SRT5
Start date: October 22, 2019
Phase: N/A
Study type: Interventional

This study will validate a predictive model that uses demographics, functional status, neurophysiology, neuroanatomy, and other potential biomarkers to predict the likelihood of a clinically significant change in impairment at the end of a robot assisted therapy intervention.The study will include magnetic resonance imaging (MRI), transcranial magnetic stimulation (TMS), and an arm exercise program consisting of robot-assisted exercise combined with functional arm exercise called transition to task training (TTT).

NCT ID: NCT04266639 Completed - Ischemic Stroke Clinical Trials

Rheo-Erythrocrine Dysfunction as a Biomarker for RIC Treatment in Acute Ischemic Stroke

ENOS
Start date: July 29, 2020
Phase: N/A
Study type: Interventional

This study aims to investigate whether Remote Ischemic Conditioning (RIC) improves rheo-erythrocrine dysfunction in acute ischemic stroke